Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke.
Bottom Line: Hematoxylin and eosin staining revealed significant 15% and 30% reductions in striatal infarct and peri-infarct area, and a trend of rescue against neuronal loss in the hippocampus.Human antigen immunostaining revealed 0.03% hBMSCs survived in spleen and only 0.0007% in brain.MSC migration to spleen, but not brain, inversely correlated with reduced infarct, peri-infarct, and inflammation. hBMSC transplantation is therapeutic in chronic stroke possibly by abrogating the inflammation-plagued secondary cell death.
Affiliation: From the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa.Show MeSH
Related in: MedlinePlus
Mentions: Confocal microscopy of hBMSC survival using immunofluorescent demonstrated positive expression in spleen and brain of hBMSC-transplanted stroke animals (Figure 5A). HuNu positive cells were found in the spleen and brain (Figure 5A). The mean graft survival of hBMSCs (ie, HuNu expression) in the spleen was significantly higher than that found in the brain indicating preferential hBMSC migration to the spleen (Student t test, P<0.05). An estimated 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain (Figure 5B and 5C).
Affiliation: From the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa.